Recent Acquisition Cerus Endovascular was acquired by Stryker Corporation in May 2023, indicating strengthened market presence and access to a broader customer base in the neurovascular device sector.

Innovative Technologies The company specializes in designing and manufacturing intra-saccular neurointerventional devices for intracranial aneurysm treatment, highlighting a focus on advanced, differentiating medical technologies.

Regulatory Milestones Cerus has achieved FDA 510(k) clearance for its microcatheters, demonstrating compliance with U.S. regulatory standards and potential opportunities for device adoption in clinical settings.

Funding Growth With recent Series B financing of $19 million, Cerus Endovascular shows strong investor confidence and potential for expansion of its product portfolio and market reach.

Market Positioning Operating in the niche neurovascular market with a focus on intracranial aneurysm treatment devices, Cerus presents opportunities for collaborating with hospitals, clinics, and distributors targeting minimally invasive neurointerventional procedures.